Bio Pharma Dive
AUGUST 7, 2024
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 7, 2024
Scientists think they may have found locations in the brain where schizophrenia first emerges, potentially making the neurological disorder’s onset easier to diagnose from a standard MRI brain scan.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 7, 2024
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 7, 2024
India continues to face significant challenges in boosting its organ donation rates, currently languishing at just over one per million population. Despite widespread public support, the country struggles to increase its organ donation rates, due in part to a combination of legal misconceptions, lack of awareness within the medical community, and cultural barriers.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
AUGUST 7, 2024
U.S. sales of the medicine, Rezdiffra, were more than triple analysts’ expectations, encouraging Madrigal to market it in Europe without a partner.
Rethinking Clinical Trials
AUGUST 7, 2024
In this Friday’s PCT Grand Rounds, Greg Simon and Susan Shortreed of the Kaiser Permanente Washington Health Research Institute (KPWHRI) will present “Does Starting Buprenorphine Prevent Suicidal Behavior? What Trial Should We Emulate?” The Grand Rounds session will be held on Friday, August 9, 2024, at 1:00 pm eastern. Simon is a senior investigator at KPWHRI and a research professor of psychiatry and behavioral sciences at the University of Washington.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
AUGUST 7, 2024
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
Pharmaceutical Technology
AUGUST 7, 2024
Amgen has reported a 45.9% decrease in net income to $746m in Q2 2024 compared to $1.3bn in the same period of the previous year.
Pharma Times
AUGUST 7, 2024
Researchers aim to explore and investigate axonal dysfunction in neurodegeneration
Pharmaceutical Technology
AUGUST 7, 2024
As WHO reports a high HBV burden, Aligos Therapeutics’ CEO highlighted the potential for pharma to address unmet needs.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
AUGUST 7, 2024
Explore the innovative applications of mRNA technologies beyond COVID-19 vaccines. Learn about the potential and future developments in this groundbreaking field.
Pharmaceutical Technology
AUGUST 7, 2024
Shares in Novo Nordisk slid as supply bottlenecks and a more crowded weight loss treatment space depress Wegovy sales.
pharmaphorum
AUGUST 7, 2024
BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now
Pharmaceutical Technology
AUGUST 7, 2024
The company plans to use the Series B proceeds to finance Phase I and pivotal trials for IDRX-42, licenced from Merck KGaA.
pharmaphorum
AUGUST 7, 2024
Explore how artificial intelligence and machine learning are revolutionising the medical devices sector. Learn about the innovative technologies and how companies are navigating evolving regulations in this rapidly advancing field.
Pharmaceutical Technology
AUGUST 7, 2024
Precigen also plans to raise $30m to focus on advancing its recurrent respiratory papillomatosis (RRP) candidate PRGN-2012.
pharmaphorum
AUGUST 7, 2024
Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half
Pharmaceutical Technology
AUGUST 7, 2024
The US FDA has approved Servier's VORANIGO for Grade 2 astrocytoma or oligodendroglioma harbouring IDH1 and IDH2 mutations.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
AUGUST 7, 2024
The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.
Pharmaceutical Technology
AUGUST 7, 2024
Daiichi Sankyo and MSD broadened their partnership for the development and commercialisation of three ADCs.
Pharmaceutical Commerce
AUGUST 7, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
AUGUST 7, 2024
Sangamo Therapeutics has signed an agreement with Genentech for the development of genomic medicines to treat neurodegenerative diseases.
pharmaphorum
AUGUST 7, 2024
A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled 510 patients with moderate-to-severe osteoarthritis of the knee, raising the hope it could become a non-addictive option for patients needing chronic pain relief.
Fierce Pharma
AUGUST 7, 2024
As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S. | Late Wednesday, the FDA granted approval to Amneal’s Crexont—formerly known as IPX203—which is an oral, extended-release formulation of the common Parkinson’s disease (PD) drugs carbidopa/levodopa (CD/LD).
pharmaphorum
AUGUST 7, 2024
Around 14,000 women in England may soon be able to access osteoporosis drug Eladynos from Theramex after NICE backed NHS use
Fierce Pharma
AUGUST 7, 2024
Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
AUGUST 7, 2024
FDA approves Servier's IDH 1/2 inhibitor vorasidenib as the first targeted therapy for incurable brain cancer glioma
Fierce Pharma
AUGUST 7, 2024
On the rocky road to ensuring access to gene therapy Casgevy in the U.K., Vertex and CRISPR Therapeutics are making inroads by securing a thumbs up from England’s National Institute for Health and | The cost-effectiveness regulator recommended government funding for the groundbreaking gene-editing therapy in one of its two approved indications.
Pharmaceutical Commerce
AUGUST 7, 2024
Why it is important for organizations to set long-term goals when planning for a sustainable future?
Fierce Pharma
AUGUST 7, 2024
Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? | Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
285 
Let's personalize your content